India caps trade margins on 137 cancer drugs at 30% of MRP

What the rule does

The NPPA, acting under Paragraph 19 of the Drugs (Prices Control) Order, 2013, announced on 17 Oct that the trade margin – the gap between a drug’s manufacturer price and its maximum retail price (MRP) – can no longer exceed 30% of the MRP, GST excluded. From 9 Nov, chemists and hospitals must charge the revised prices and display them on‑site and online.

Scope of the cap

A technical committee of the Directorate General of Health Services selected 137 non‑scheduled cancer medicines, covering more than 1,000 brands. The list includes high‑profile agents such as abemaciclib, nivolumab, pembrolizumab, and the combination of pertuzumab‑trastuzumab. All branded and generic versions, whether imported or made in India, fall under the order.

Expected price impact

The government’s affidavit, presented by Additional Solicitor General Aishwarya Bhati, estimates that limiting margins could cut MRPs by 20‑70%, translating into about ₹2,500 crore in patient savings each year. The NPPA’s own calculations suggest that for drugs where the current margin is around 170‑700%, the new ceiling could lower the pre‑tax MRP by roughly 64%.

How the ceiling is calculated

The cap is anchored to the price‑to‑stockist (PTS) that manufacturers actually received in March 2026, averaged over the previous year if a drug had no sales in that month. The permissible pre‑tax MRP is therefore 1.43 times the PTS, which equates to a 42.86% markup over the manufacturer’s price.

What the rule does not change

The order does not touch the manufacturer’s selling price, so drugs that are priced high at the source will remain expensive for patients. It also relies on hospitals to honour the new MRPs; enforcement will be handled by state drug controllers.

Industry and expert reaction

Girdhar Gyani, director general of the Association of Healthcare Providers, welcomed the clarity of the rule but warned that a 30% trade margin should not be confused with a 30% profit margin for hospitals. "The basis of calculation and its applicability at each supply‑chain stage must be clearly communicated," he said.

Mayur Sirdesai, co‑founder of Somerset Indus Capital, noted that affordability must be viewed across the entire cancer‑care pathway – from screening to treatment – and that a margin cap alone will not solve the high cost of therapy.

Civil‑society voices echoed the same caution. KM Gopakumar of the Third World Network said hospitals could offset reduced margins by hiking fees for diagnostics, consumables or bundled packages, a pattern observed after the 2017 cardiac‑stent price cap.

Past precedents

The government has used the same emergency power before: in 2014 for diabetes and heart‑disease drugs, in 2019 for 42 cancer medicines, and during the Covid‑19 pandemic for oxygen‑related equipment. Those interventions have shown that margin caps can bring down MRPs, but broader price rationalisation is often needed to achieve lasting affordability.

What patients can do now

Patients can check the revised prices on the NPPA’s “Pharma Sahi Daam” app or website. Any over‑charging can be reported to the NPPA, which is mandated to act on complaints. The health ministry says it will monitor the impact closely and may update the list as market conditions evolve.

Outlook

If hospitals comply and the cap is enforced uniformly, the policy could deliver tangible savings for millions of Indian cancer patients. However, the ultimate benefit will depend on whether ancillary charges are kept in check – a task that will require coordinated oversight across the health‑care ecosystem.